文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

光谱CT金属伪影减少在宫颈癌腔内近距离治疗中的前瞻性研究

Metal artifact reduction in spectral computed tomography for intracavity brachytherapy in cervical cancer patients: a prospective study.
PubMed 文献 · Radiat Oncol · 2025-12-01

结果显示VMI+MAR显著降低伪影指数并提高SNR和CNR,140 keV+MAR在伪影减少、几何精度和勾画适宜性间取得最佳平衡。

要点

  • VMI+MAR在所有能量下显著降低宫颈和直肠伪影指数(p<0.05)。
  • 140 keV+MAR的SNR和CNR最高、AI最低,主观评分最优(p<0.001)。
  • 140 keV+MAR的DSC最高、HD95最低,靶区和危及器官勾画可重复性最佳。

核心结论

  • 对于所研究的病例和成像流程,高能VMI联合MAR(尤其140 keV+MAR)在伪影减少、几何精度和临床勾画适宜性间提供最有效平衡。

研究设计与样本

  • 在40至140 keV重建VMI+MAR与VMI+无MAR图像,比较客观指标、主观评分、几何畸变和勾画一致性。

主要发现

  • VMI+MAR较VMI+无MAR显著降低宫颈AI(相对降低34.74%-88.51%)和直肠AI(相对降低11.31%-81.35%),所有能量均p<0.05。
  • SNR从0.70–1.00提高至1.75–1.97,CNR从90 keV起显著改善(p<0.05)。
  • 140 keV+MAR的SNR和CNR最高、AI最低;主观伪影减少和勾画偏好评分显著更高(p<0.001)。
  • 随VMI能量从40增至140 keV,长轴从8.10 mm降至6.17 mm,短轴从6.93 mm降至5.55 mm,L/S趋近1(p<0.001)。
  • 140 keV+MAR在所有能量-MAR组合中DSC最高、HD95最低。

关键数值与推荐

  • VMI+MAR组宫颈AI相对降低34.74%-88.51%,直肠AI相对降低11.31%-81.35%(所有能量p<0.05)。
  • SNR从0.70–1.00提高至1.75–1.97;CNR从90 keV起显著改善(p<0.05)。
  • 140 keV+MAR主观伪影减少和勾画偏好评分显著更高(p<0.001)。
  • 长轴从8.10 mm降至6.17 mm、短轴从6.93 mm降至5.55 mm(40-140 keV),L/S趋近1(p<0.001)。
  • 140 keV+MAR的DSC最高、HD95最低。

临床怎么用

  • 宫颈癌腔内近距离治疗光谱CT可采用高能VMI(尤其140 keV)联合MAR以减少施源器金属伪影。
  • 该组合有助于提高靶区和危及器官勾画的一致性与可重复性。

局限性

  • 结论仅适用于所研究的病例和成像流程。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This study aims to evaluate the effectiveness of combining virtual monochromatic images (VMI) with metal artifact reduction (MAR) algorithms in reducing metal artifacts in cervical cancer patients undergoing intracavitary brachytherapy. MATERIALS AND METHODS: Fifty cervical cancer patients scheduled for intracavitary brachytherapy underwent spectral computed tomography (CT) images. VMI + MAR/no-MAR were reconstructed at energies ranging from 40 to 140 keV. CT attenuation and image noise (standard deviation) were measured to calculate the signal-to-noise ratio (SNR), contrast-to-noise ratio (CNR) for the most prominent artifacts, and the artifact index (AI) for the cervix, bladder, and rectum. Objective metrics were compared between the VMI + MAR and VMI + no-MAR groups. Subjective image quality was evaluated using a 5-point Likert scale, focusing on artifact reduction, soft tissue contrast, and contouring preference. Geometric distortion was assessed by measuring the long axis, short axis, and long-to-short axis ratio (L/S) of the titanium applicator. Contouring consistency was quantified using the Dice Similarity Coefficient (DSC) and 95th percentile Hausdorff Distance (HD95) between two radiation oncologists. RESULTS: VMI + MAR significantly reduced the AI for the cervix (relative 34.74%-88.51% reduction) and rectum (relative 11.31%-81.35% reduction) compared to VMI + no-MAR across all energies (all p < 0.05). SNR increased from 0.70–1.00 to 1.75–1.97, and CNR improved significantly from 90 keV onwards (p < 0.05). 140 keV + MAR achieved the highest SNR and CNR with the lowest AI. Subjective assessment further confirmed that 140 keV + MAR offered the best balance between artifact reduction and soft tissue contrast, with significantly higher scores for artifact reduction and contouring preference (p < 0.001). Distortion analysis showed that with increasing VMI energy, long (40-140 keV: from 8.10 to 6.17 mm) and short axes (40-140 keV: from 6.93 to 5.55 mm) decreased, and L/S approached 1 (p < 0.001). Contouring consistency analysis further demonstrated that 140 keV + MAR achieved the highest DSC and lowest HD95 among all energy-MAR combinations, indicating superior reproducibility of target and organ-at-risk delineations. CONCLUSIONS: For the investigated cases and imaging procedures, high-energy VMI combined with MAR, particularly 140 keV + MAR, provided the most effective balance of artifact reduction, geometric accuracy, and clinical contouring suitability.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Sun Y, Chen Y, Zeng Z, et al. Metal artifact reduction in spectral computed tomography for intracavity brachytherapy in cervical cancer patients: a prospective study. Radiat Oncol. 2025. PMID: 41327225. doi:10.1186/s13014-025-02767-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。